BioVersys Appoints Dr. Daniel Ritz as Chief Scientific Officer

BioVersys AG, a clinical stage biopharmaceutical company based in Basel, Switzerland, has announced the appointment of Dr. Daniel Ritz as Chief Scientific Officer. Dr. Ritz succeeds Dr. Sergio Lociuro, who is retiring after a decade of service. Dr. Marc Gitzinger, CEO of BioVersys, expressed gratitude for Dr. Lociuro's contributions, particularly in advancing two key clinical stage assets.

Dr. Ritz brings extensive experience in the anti-infective field. His previous roles include leading the Biology Technologies and Discovery group at Idorsia Pharmaceuticals. Dr. Ritz's expertise includes developing antibiotic compounds and researching infection biology. He will now focus on BioVersys's early-stage pipeline and collaborations, such as the BV500 program partnership with Shionogi.

Dr. Ritz expressed his enthusiasm for joining BioVersys, aiming to develop effective drugs for patients suffering from multi-drug resistant infections.